A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Women

Not Applicable

Completed

Conditions: Pregnancy, High Risk
Stress, Psychological
Iron-deficiency

Interventions: Other: Placebo in capsule form
Dietary Supplement: Probiotic LP299v 10x10 colony forming units in capsule form

Registration Number: NCT03646487

Lead Sponsor: University of Illinois at Chicago

Brief Summary: The goal of this randomized supplementation feasibility trial is to learn about the feasibility and preliminary efficacy of the probiotic, lactobacillus plantarum 299v (Lp299v), in pregnant individuals at-risk for iron deficiency anemia.

The main questions it aims to answer are:

* Is daily oral Lp299v a feasible and tolerable intervention for pregnant individuals to uptake?

* Does daily oral Lp299v in pregnancy impact maternal and neonatal cord hematological and iron status parameters?

Participants will be randomly assigned to one of two treatment groups: daily intake or probiotic Lp299v + prenatal vitamin with iron or placebo + prenatal vitamin with iron from 15-20 weeks of gestation through delivery.

Researchers will compare the two treatment groups to see if there is a difference in the feasibility of the intervention and the preliminary efficacy on maternal and neonatal cord hematological and iron status parameters.

Detailed Description: The most prevalent micronutrient deficiency in the United States (U.S.) is iron; a large majority of cases of iron deficiency (ID) and iron deficiency anemia (IDA) occur among pregnant women. During pregnancy, maternal iron stores are used for the growing fetus, maternal red blood cell (RBC) expansion, and placental growth and development, thus increasing the risk for ID and IDA. Across all trimesters of pregnancy in the U.S., it is estimated that 18% of individuals have ID and 5% have IDA, and within the third trimester, the prevalence of ID exceeds 27%. Prevalence of IDA is even greater among those who identify as Black or low-income. Maternal ID and IDA are associated with increased risk of preterm birth, low infant birth weight, maternal and fetal mortality, and irreversible infant neurocognitive defects. To meet this increasing requirement for iron and to optimize maternal iron nutrition, the Recommended Dietary Allowance for pregnancy is 27 mg/day of iron. However, given the continued high rates of maternal ID and IDA and only modest adherence to daily prenatal vitamins containing iron, alternative approaches to optimizing iron nutrition in pregnancy are needed.

Research has shown that one-time or short-term dosing of the probiotic Lactobacillus plantarum 299v (Lp299v) enhances iron absorption in non-pregnant populations. However, few studies have examined the effect of long-term supplementation on body iron stores. While probiotics are considered safe to consume in pregnancy, only one Lp299v supplementation trial has been conducted during the gestational period to evaluate its effects on maternal iron stores and risk of IDA. This study, among iron-sufficient pregnant Swedish women, showed a significantly lower decline in iron stores and a significantly lower prevalence of IDA in the third trimester among those randomized to Lp299v compared to standard care control.

These results offer potential positive effects for the role of Lp299v in maintaining maternal iron status among those starting pregnancy with sufficient iron stores and who receive care in a decentralized publicly funded healthcare system. However, no studies have evaluated the effect of Lp299v on maternal iron status among individuals at risk for IDA in pregnancy in the U.S., nor have studies extended findings to neonatal iron status. Moreover, it is unknown if positive feasibility and preliminary efficacy would persist in a U.S.-based health care setting with racially, ethnically, and socioeconomically diverse pregnant individuals. Therefore, the objectives of this study were as follows. First and foremost, we examined the feasibility of daily oral Lp299v maternal supplementation taken from the early second trimester through birth. Second, we explored the preliminary efficacy of Lp299v intake on maternal (at-risk for IDA defined as hemoglobin (Hb) between 10.0-12.0 g/dL) and neonatal cord hematological and iron status parameters compared to controls in an urban U.S. academic medical center with a racially, ethnically, and socioeconomically diverse patient population.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 20

Inclusion Criteria

a 1st trimester hemoglobin (Hb) of 10.0 - 11.9 g/dl demonstrating ID or risk for prenatal ID
singleton
naturally conceived pregnancy
< 20 weeks gestation
18 - 45 years of age
sufficient fluency in English to complete study forms
refrain from non-study dietary and pre-/probiotic supplements while enrolled in the study

Exclusion Criteria

oral antibiotic use within the past 2 months
autoimmune disease
infection
receiving steroid treatment
bariatric surgery
inflammatory bowel disease
hyperemesis
hematologic disorder (e.g., sickle cell disease)
current tobacco use
substance abuse in the last 6 months
other chronic disorders such as type 2 diabetes

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo in capsule form	Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
Probiotic LP299v	Probiotic LP299v 10x10 colony forming units in capsule form	Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.

Primary Outcome Measures

Name	Time	Method
Mean Adherence to the Supplement Regimen	15 weeks gestation through delivery, an average of 25 weeks	Mean adherence to the supplement regimen using Pillsy smart bottles and standard pill counts.

Secondary Outcome Measures

Name	Time	Method
Infant Iron	delivery	Mean infant serum iron (µg/dL) from cord blood at delivery.
Maternal Hemoglobin	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal serum hemoglobin (g/dl) from baseline to delivery
Infant Total Iron Binding Capacity	delivery	Mean infant total iron binding capacity (µmol/L) from cord blood at delivery.
Infant Transferrin Saturation	delivery	Mean infant transferrin saturation (%) from cord blood at delivery.
Number of Treatment-emergent Adverse Events Related to GI Symptoms	15 weeks gestation through delivery, an average of 25 weeks	Adverse events were captured using the Maternal Adherence Form beginning with the first pill refill visit through delivery. number of participants reporting adverse GI events
Maternal Serum Ferritin	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal serum ferritin (ng/mL) from baseline to delivery
Infant Hematocrit	delivery	Mean infant serum hematocrit (%) from cord blood at delivery.
Maternal Hematocrit	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	Change in mean maternal serum hematocrit (%) from baseline to delivery
Maternal Iron Deficiency Anemia	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	Number of participants who had iron deficiency anemia (IDA) at delivery. Hemoglobin, obtained from the Complete Blood Count, was used to define trimester-specific maternal IDA, with a downward correction of 0.8 g/dL for Black women. At the time of the study, it was recommended to use a race-adjusted cut-point for IDA. However, this race-adjusted cut-point was recently determined to be unfounded. IDA ranges included hemoglobin ≤11 g/dL for the first trimester, ≤10.5 g/dL for the second trimester, and ≤11 g/dL for the third trimester. IDA ranges with the correction for Black women were hemoglobin ≤10.2 g/dL for the first trimester, ≤9.7 g/dL for the second trimester, and ≤10.2 g/dL for the third trimester.
Maternal Iron	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal serum iron (µg/dL) from baseline to delivery
Infant Serum Ferritin	delivery	Mean infant serum ferritin (ng/mL) from cord blood at delivery.
Maternal Total Iron Binding Capacity	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal total iron binding capacity (µmol/L) from baseline to delivery
Maternal Transferrin Saturation	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal transferrin saturation (%) from baseline to delivery
Maternal High-sensitivity C-reactive Protein (Hs-CRP)	Assessed at baseline (i.e., 15-20 weeks gestation) through delivery; mean change from baseline to delivery is reported.	change in mean maternal high-sensitivity C-reactive protein (hs-CRP) (mg/L) from baseline to delivery
Infant Hemoglobin	delivery	Mean infant serum hemoglobin (g/dl) from cord blood at delivery.